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Abstract We have cloned and sequenced mouse utrophin 
cDNA, and successfully expressed full length utrophin (400 
kDa) in both muscle and non-muscle cells. The expression of 
recombinant utrophin is compared with that of its homologue, 
dystrophin (427 kDa). We demonstrate that recombinant 
utrophin is targeted into agrin-induced acetylchofine receptor 
(AChR) clusters, while recombinant dystrophin is evenly 
distributed along cell membranes in cultured Sol 8 muscle cells. 
This observation suggests that utrophin and dystrophin may 
interact with different cytoskeletal proteins. The C-terminal 
domains are found to be responsible for the association of 
utrophin with AChR clusters. 
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1. Introduction 
Dystrophin is part of an elaborate protein complex that 
bridges the inner cytoskeleton and the extracellular matrix 
[1]. In the X-chromosome-linked Becker and Duchenne mus- 
cular dystrophy [2], mutations in dystrophin disrupt the in- 
tegrity of the complex, leading to fragility in muscle mem- 
brane and muscle necrosis. Utrophin, the discovered 
autosomal homologue of dystrophin, shares considerable se- 
quence homology with dystrophin [3]. In addition to structur- 
al similarities, utrophin and dystrophin are also found to be 
associated with identical or similar proteins [4,5]. In both 
DMD patients and mdx mice where dystrophin is absent, 
utrophin is upregulated [6]. These observations lead to the 
suggestion that these two proteins may have similar func- 
tion(s), raising the hope that still higher levels of utrophin 
could ameliorate symptoms of muscular dystrophy by substi- 
tuting for dystrophin [7]. On the other hand, utrophin and 
dystrophin have different issue distributions and are differen- 
tially regulated uring development [3,8]. At the adult neuro- 
muscular junction, utrophin is also found to be exclusively 
localized with nerve-induced AChR clusters while dystrophin 
is enriched at the junction [6]. The above observations suggest 
that, despite structural similarities, there may be substantial 
functional differences between utrophin and dystrophin, e.g. 
at the neuromuscular junction. As a beginning step to study- 
ing the structural and functional differences between utrophin 
and dystrophin, we have cloned, sequenced, and expressed the 
full length mouse recombinant u rophin. We demonstrate hat 
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recombinant utrophin is targeted into agrin-induced AChR 
clusters while recombinant dystrophin is evenly distributed 
along cell membranes in cultured Sol 8 cells. We also show 
that the C-terminus of utrophin is responsible for targeting 
recombinant utrophin into agrin-induced AChR clusters. 
2. Materials and methods 
2.1. cDNA library, cloning and sequencing 
A 1.9 kb human C-terminus utrophin cDNA fragment [9] obtained 
from ATCC was used as a probe to screen an oligo dT-primed cDNA 
library constructed using mRNA from a BC3H1 cell line. Approxi- 
mately 3 kb of C-terminal mouse utrophin was isolated and used in 
further screening of a randomly primed cDNA library constructed 
using mRNA from adult mouse lung (Stratagene, La Jolla, CA). 
Library screening, plaque purification, and DNA isolation were per- 
formed as described previously [10]. All fragments of mouse utrophin 
cDNA obtained from library screening were subcloned into Bluescript 
KS II + vectors (Stratagene) and further ligated together into a single 
continuous 11 kb coding sequence. DNA sequencing was performed 
both manually using designed oligonucleotides and with an automated 
sequencer using a Taq Dyedeoxy Terminator cycle sequencing kit 
(Applied Biosystems, Foster city, CA). The sequence was determined 
on both strands. 
2.2. Expression constructs 
The 11 kb full length mouse utrophin cDNA was engineered atthe 
5'-end with a Flag epitope tag by special oligo design and subcloned 
into a Bluescript KS II + vector containing the cytomegalovirus 
(CMV) promoter and SV40 poly A tail (Fig. 2). The deletion mutant, 
MU-1 (Fig. 4), was generated by subcloning a cDNA fragment con- 
taining a stop codon at nucleotide 3416 of the full length mouse 
utrophin into the same expression vector. MU-2 and MU-3 were 
generated by specific restriction enzyme digestion, and subcloned 
into expression constructs. Each of the three mutants was tagged 
with Flag epitope after the first initiation codon, methionine. The 
dystrophin expression construct was pMDA, which contained the 
full length murine dystrophin cDNA regulated by 6.5 kb MCK pro- 
moter/enhancer/first intron fragment [11]. 
2.3. Maintenance and transfection of cells 
QT-6 cells and Sol 8 cells were maintained and transfected as pre- 
viously described [12,13]. Agrin-secreted CHO cells, gifts from R. 
Scheller, were cultured as described previously [14]. The recombinant 
agrin was concentrated from agrin-secreted culture medium using 
Centriprep-30 (Amicon Inc., MA). 
2.4. Immunofluorescence andWestern blotting 
Fused myotubes were treated with the isolated form of agrin from 
CHO cells for 12-14 h, followed by incubation with rhodamine-la- 
beled c~-bungarotoxin (BGT) at 37°C for 1 h. These cells were then 
fixed, permeablized and blocked as described previously [12]. After 
blocking, each glass coverslip was taken out and incubated with the 
desired primary antibody, as detailed below. Anti-Flag antibody 
(1:50) was from Eastman Kodak Company, NY; anti-C-terminus of 
utrophin (1:30) was generated by the authors against a peptide con- 
taining the last 10 amino acids; anti-C-terminus of dystrophin (1:8) 
was obtained from Novocastra, UK (DYS-2). Following primary 
antibody treatment, he cells were incubated with the FITC- or 
TRITC-conjugated secondary antibody (Boehringer Mannheim 
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Fig. 1. Sequence comparison of the actin (A), the syntrophin (B) and the 13-dystroglycan (C) binding domains of mouse utrophin (MUTR) 
with those of human utrophin (HUTR), and chicken (CDYS), mouse (MDYS), and human (HDYS) dystrophins. The boxed areas indicate res- 
idues that differ between utrophin and dystrophin. ABS1-3: major actin binding regions; CaM: a putative calmodulin binding site; CaCa: 
calcium binding EF-hands. The inset is a schematic representation of utrophin showing the location of domains A, B, and C. 
Corp., IN). For Western blotting, proteins from membrane fractions 
isolated from both transfected and nontransfected cells were separated 
on 6% SDS PAGE gel, transferred onto a nitrocellulose sheet, blocked 
with 5% nonfat milk and incubated with a primary antibody (anti- 
Flag: 1-1000; anti-C-terminus ofutrophin: 1-500; anti-C-terminus of
dystrophin: 1-30), followed by a peroxidase-conjugated s condary 
antibody. Protein bands were visualized using the ECL method (Du- 
Pont, MA). 
3. Results and discussion 
3.1. Cloning and sequencing of  full length mouse utrophin 
Before this study, only the primary sequence of the human 
utrophin was known. Since much could be learned from the 
comparison of a new sequence to known ones of other related 
proteins, we set out to clone the cDNA that encoded the 
entire open reading frame of mouse utrophin. This was 
achieved through extensive library screening. Parts of C-ter- 
minal mouse utrophin cDNA from both the BC3H1 library 
and the mouse lung library were sequenced to verify that there 
was no polymorphism among these tissues. The complete se- 
quence of the full length mouse utrophin cDNA was subse- 
quently obtained. The availability of mouse utrophin sequence 
permitted the comparison of utrophins (human and mouse) 
with dystrophins (human, mouse and chicken), particularly 
the identification of utrophin sequences that are conserved 
between species, but differ from dystrophin. This may also 
assist the identification of functional domain(s) of utrophin 
through mutagenesis. 
Fig. 1 compares the sequences of potentially important do- 
mains of utrophins and dystrophins. Like its orthologue and 
homologue, mouse utrophin contains an actin binding do- 
main, a long region containing multiple repeats followed by 
a WW/WWP domain [4], a calcium binding EF-hand domain, 
a cysteine-rich domain, and two helical domains at the C- 
terminus. Mouse utrophin shares 84% identity at the nucleo- 
tide level and 87% identity at the amino acid level with human 
utrophin. Sequences at both ends of the molecule are particu- 
larly well conserved between the two species: there was 92°,4 
identity for the first 250 amino acids at the N-terminus; the 
best conserved region is found for residues starting from the 
WW/WWP domain through the C-terminus, with 97% iden- 
tity, pointing to the potential functional significance of this 
region. The same regions of utrophin also show 70-80% iden- 
tity to those of dystrophin. Within the actin binding domain 
(Fig. 1A) [4], the syntrophin binding domain (Fig. 1B) [15], 
and the 13-dystroglycan binding region (Fig. 1C) [16], there are 
some amino acid residues which are nearly identical between 
mouse and human utrophins but are quite different from 
those in the dystrophins. Perhaps, these small differences in 
the primary structure could lead to behavioral differences be- 
tween utrophins and dystrophins, e.g. in actin binding regu- 
lated by calmodulin [4]. Such small differences in the primary 
structure could also be responsible for differences in their roles 
in AChR clustering, as shown below. 
3.2. Expression of  mouse utrophin 
For functional analysis, we ligated partial mouse utrophin 
cDNAs to form an 11 kb full length cDNA (10.3 kb coding 
sequence). This full length cDNA was tagged, subcloned into 
an expression vector containing the CMV promoter (Fig. 2), 
and transiently transfected into QT-6 fibroblasts. Membrane 
fractions were isolated and subjected to Western blot detec- 
tion using either an anti-Flag antibody (1 and 2, Fig. 2A) or 
an antibody against he last 10 amino acids of the C-terminus 
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Fig. 2. Expression of recombinant u rophin and dystrophin in cultured cells. Top: Schematic representation f the utrophin expression con- 
struct. Bottom: Immunoblotting of utrophin expression in (A) QT-6 and (B) Sol 8 cells. In both cell lines, an anti-Flag antibody (2) and a 
polyclonal antibody against the last 10 amino acids of the C-terminus of human utrophin (4) were used for detection; lanes 1 and 3 were non- 
transfected cells used as negative controls for 2 and 4, respectively. Dystrophin expression (C) in Sol 8 cells was detected using a monoclonal 
antibody against he last 17 amino acids of human dystrophin (2). Nontransfected cells were used as negative control (1). A skeletal muscle 
membrane fraction was used as positive control (3). 
(3 and 4, Fig. 2A). Both antibodies recognized a protein of 
400 kDa. There was no detectable protein band around 400 
kDa in nontransfected cells. 
While the expression of full length recombinant utrophin 
was successfully demonstrated using QT-6 cells, this cell line 
was not suitable for further functional analysis, due to the 
lack of necessary components for producing agrin-induced 
receptor clusters. Instead, we chose Sol 8 cells, a cell line 
derived from the mouse soleus muscle and used previously 
in studying the regulation of AChR subunit expression [13]. 
Membrane fractions from nontransfected and transfected Sol 
8 cells were isolated and proteins were detected by an anti- 
Flag (lanes 1 and 2, Fig. 2B) and an anti-C-terminal utrophin 
antibody (lanes 3 and 4, Fig. 2B). The anti-C-terminus anti- 
body not only recognized recombinant utrophin (lane 4, Fig. 
2B), as demonstrated by the elevated protein density for the 
same amount of protein loading, but also recognized endo- 
genous utrophin (lane 3, Fig. 2B). Both recombinant and en- 
dogenous utrophins detected by the anti-C-terminus antibody 
have the same molecular weight as the protein recognized by 
the anti-Flag antibody (lane 2, Fig. 2B). These results demon- 
strate the successful expression of recombinant utrophin in 
Sol 8 cells, albeit with much lower efficiency than in QT-6 
cells. 
For comparison, the expression of full length recombinant 
dystrophin was also examined in Sol 8 cells (Fig. 2C). A 
mouse skeletal muscle membrane fraction was used as positive 
control. There was no detectable ndogenous dystrophin in 
Sol 8 cells (lane 1, Fig. 2C). In Western blots of membrane 
proteins from Sol 8 cells transiently transfected with dystro- 
phin cDNA, the expressed protein migrated at the same posi- 
tion as that detected in the skeletal muscle membrane fraction. 
3.3. Association of recombinant utrophin and dystrophin with 
agrin-induced AChR clusters 
The successful expression of full length mouse utrophin 
allows us to analyze functional similarities and differences 
between utrophin and dystrophin. We choose to assess the 
association of utrophin and dystrophin with agrin-induced 
AChR clusters, Although the exact mechanism by which 
agrin-induced AChR clustering is not clear, recent studies 
suggest hat agrin released by the nerve can induce molecular 
reorganization i volving AChR clusters at the motor endplate 
via a MuSK receptor complex [17,18]. It is speculated that 
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Fig. 3. Colocalization of recombinant utrophin but not dystrophin with agrin-induced AChR clusters in Sol 8 cells. Panels on the left (a-e) are 
staining for receptors. Panels on the right are staining for: (a') endogenous utrophin; (b') endogenous dystrophin; (c') recombinant utrophin; 
(d') recombinant dystrophin; and (e') control experiment with no primary antibody. Instead of using the antibody against he C-terminus for 
endogenous utrophin (a'), an anti-Flag antibody was used as the primary antibody for recombinant utrophin (c'). A monoclonal antibody 
against the last 17 amino acids of human dystrophin was used for dystrophin (b' and d'). Bar: 40 ~tm. 
utrophin may act as a structural linker in connecting rapsyn- 
initiated small clusters to form large receptor clusters in re- 
sponding to the binding of agrin to its receptor complex [12]. 
Because AChR clustering had never been documented in 
Sol 8 cells, we first used immunostaining to show that Sol 8 
cells can produce both spontaneously formed and agrin-in- 
duced AChR clusters (Fig. 3). A comparison with previous 
studies showed that the number of spontaneously formed 
clusters in Sol 8 was much lower than that produced in C2 
myotubes [12]. However, the number of AChR clusters in Sol 
8 cells could be drastically increased by agrin, from 1-2 per 
field (420 lam × 420 Ixm) to 40 + 5 per field. Rapsyn (data not 
shown) and utrophin both colocalized with all clusters (Fig. 
3a'). Cluster length ranged from 6 to 70 ~tm. Consistent with 
Western blot analysis (Fig. 2C), immunofluorescence staining 
showed no detectable endogenous dystrophin (Fig. 3b'). 
To determine whether recombinant utrophin is targeted 
into agrin-induced large receptor clusters, we transfected the 
Flag-tagged utrophin construct into Sol 8 cells. As shown by 
immunostaining, recombinant utrophin was colocalized with 
agrin-induced large receptor clusters (Fig. 3c'). Control ex- 
periments (secondary antibody alone) ruled out the possibility 
that the staining of clusters resulted from bleeding through 
from the receptor channel (Fig. 3e'). 
We have also transfected recombinant dystrophin into Sol 8 
cells. Recombinant dystrophin was evenly associated with 
plasma membrane and not colocalized with AChR clusters 
(Fig. 3d'), regardless of the level of expression. Thus our 
results have demonstrated that recombinant utrophin and 
dystrophin show differential association with AChR clusters 
in Sol 8 cells, providing evidence that it is utrophin and its 
complex that are specifically associated with AChR clusters. 
This association may result from the interaction of utrophin 
with synapse specific protein(s), such as AChR itself, rapsyn, 
syntrophin or other unidentified protein(s). Meanwhile, dys- 
trophin may play a role in the maintenance of muscle mem- 
brane stability by interacting with different protein(s). Support 
for this hypothesis can be found in the observation that anti- 
132 syntrophin staining was only present at NMJ in rat skeletal 
muscle, while anti-~l syntrophin, an isoform of 132 syntrophin, 
gave strong labeling of both sarcolemma and NMJ in normal 
rat and mouse muscle, resembling the localization of dystro- 
phin [19]. In addition, anti-~a syntrophin gave similar but 
much weaker labeling in mdx mouse muscle where dystrophin 
was absent. Therefore, 132 syntrophin appears to be specific to 
the NMJ, as is utrophin, while ctl syntrophin is more likely 
associated with dystrophin. 
The successful expression of functional full length mouse 
recombinant utrophin also enables future research on reveal- 
ing possible functional differences between utrophin and dys- 
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Fig. 4. Expression of utrophin mutants. Left: Schematic representations of expression constructs of wild type utrophin (WU) and utrophin mu- 
tants (MU-1, MU-2 and MU-3). Right: Immunoblotting of MU-1 (b), MU-2 (c) and MU-3 (d) expression i  Sol 8 cells. Membrane proteins 
from nontransfected cells were used as negative control (a). An anti-Flag antibody was used for mutant expression detection. 
trophin beyond the NMJ [20]. Previous studies indicate that 
utrophin expression is upregulated in both mdx mice and 
DMD patients where dystrophin is absent, suggesting that 
utrophin may compensate for the loss of dystrophin. On the 
other hand, the binding of utrophin and dystrophin to F-actin 
are regulated to different extents by Ca2+/calmodulin [4]. Thus 
the proposal of using overexpression f utrophin as a poten- 
tial therapy for DMD patients may be over-simplified. In this 
regard, the availability of full length functional utrophin ex- 
pression construct may allow us in the near future to system- 
atically address this important issue. 
3.4. C-terminal domains are responsible for targeting 
recombinant utrophin into AChR clusters 
To understand at the molecular level such differential loca- 
lization of utrophin and dystrophin with AChR clusters, we 
generated three utrophin deletion mutants (Fig. 4). MU-1 
contained N-terminal domain and small portion of central 
AChR 
AChR MU-1 
AChR 
MU-2 
Q 41 
"i MU-3 
Fig. 5. Association of utrophin mutants with agrin-induced AChR clusters. Panels on the left (a-c) are staining for receptors. Panels on the 
right are staining for: (a') MU-1, (b') MU-2, and (c') MU-3. An anti-Flag antibody was used. Bar: 20 pm. 
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rod domain; MU-2 contained most of the central rod domain 
and C-terminal domain(s); MU-3 contained only C-terminal 
domain(s), which includes the WW/WWP domain [4], a cal- 
cium binding EF-hand domain, a cysteine-rich domain, and 
the syntrophin binding domain. Expression vectors containing 
these mutant cDNAs driven by the CMV promoter were tran- 
siently transfected into Sol 8 cells. Protein expressions were 
determined by Western blot analysis and colocalization were 
examined by immunostaining with the anti-Flag antibody. 
Both MU-1 and MU-2 were expressed as determined by Wes- 
tern blot analysis (Fig. 4). However, in contrast o MU-1, 
which was evenly distributed along the plasma membrane 
(Fig. 5a'), MU-2 was targeted into AChR clusters (Fig. 
5b'). A chimera between utrophin and dystrophin with the 
3.7 kb N-terminus of the cDNA derived from dystrophin 
and the rest from utrophin also showed preferential localiza- 
tion with AChR clusters (data not shown). These observations 
suggested that the N-terminal domain of utrophin was not 
important for targeting utrophin into AChR clusters in Sol 
8 cells. Expression of MU-3 was too low to be detected on 
Western blots (Fig. 4). However, immunostaining clearly in- 
dicated that MU-3 was also targeted into agrin-induced 
AChR clusters (Fig. 5c'). Interestingly, the majority of myo- 
tubes only showed low levels of MU-3 expression. The small 
number of myotubes with mild to high level expression of 
MU-3 were morphological ltered and were characterized by 
thin, short, and irregular shapes (data not shown), a possible 
result of a dominant negative ffect. 
The above data suggest hat domain(s) responsible for tar- 
geting utrophin into AChR clusters reside within the C-termi- 
nus. N-terminal and central rod domains may play roles in the 
stability of the utrophin protein and may contribute to the 
localization of the protein, but are apparently not necessary 
for targeting utrophin into AChR clusters. 
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